Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations
Sponsor: AstraZeneca
Terminated
Lack of accrual
Other terminated trials from AstraZeneca
Other EGFR Gene Mutation trials with similar outcome
This PHASE1/PHASE2 trial investigates EGFR Gene Mutation and Nonsmall Cell Lung Cancer and is currently terminated or withdrawn. AstraZeneca leads this study, which shows 18 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
18 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Status: Unknown → Terminated
-
Jul 2024 — Aug 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 13 earlier versions
-
Feb 2022 — Feb 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2018 — Mar 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2018 — Sep 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1_PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2017 — May 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Bristol-Myers Squibb
- Chul Kim
- Hackensack Meridian Health
- Walter Reed National Military Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .